Ekso Bionics (EKSO) Stock Price, News & Analysis

Company Overview

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.

Key Stats

• Today's Range: $0.36 to $0.43
• 50-Day Range: $0.36 to $0.51
• 52-Week Range: $0.34 to $1.53
• Volume: 4.28 million shs
• Average Volume: 776,676 shs
• Market Capitalization: $10.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.50
• Consensus Rating: Buy

Ekso Bionics Stock Analysis - MarketRank™

Ekso Bionics scored higher than 55% of companies evaluated by MarketBeat, and ranked 883rd out of 1,850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Ekso Bionics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ekso Bionics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ekso Bionics are expected to grow in the coming year, from ($0.48) to ($0.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ekso Bionics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ekso Bionics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ekso Bionics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.58% of the float of Ekso Bionics has been sold short.

Short Interest Ratio / Days to Cover

Ekso Bionics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ekso Bionics has recently decreased by 25.23%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ekso Bionics does not currently pay a dividend.

Dividend Growth

Ekso Bionics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.58% of the float of Ekso Bionics has been sold short.

Short Interest Ratio / Days to Cover

Ekso Bionics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ekso Bionics has recently decreased by 25.23%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.08

News Sentiment

Ekso Bionics has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Ekso Bionics this week, compared to 1 article on an average week.

Search Interest

2 people have searched for EKSO on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Ekso Bionics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ekso Bionics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.00% of the stock of Ekso Bionics is held by insiders.

Percentage Held by Institutions

Only 6.42% of the stock of Ekso Bionics is held by institutions.

EKSO Stock Analysis - Frequently Asked Questions

How have EKSO shares performed this year?

Ekso Bionics' stock was trading at $0.61 at the start of the year. Since then, EKSO stock has decreased by 38.6% and is now trading at $0.3743.
View the best growth stocks for 2025 here.

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) issued its quarterly earnings results on Monday, May, 5th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01. The company had revenue of $3.38 million for the quarter, compared to the consensus estimate of $4.62 million. Ekso Bionics had a negative trailing twelve-month return on equity of 83.09% and a negative net margin of 62.95%.
Read the conference call transcript.

When did Ekso Bionics' stock split?

Shares of Ekso Bionics reverse split on the morning of Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Who are Ekso Bionics' major shareholders?

Top institutional shareholders of Ekso Bionics include Armistice Capital LLC (7.03%) and Cresset Asset Management LLC (0.93%). Insiders that own company stock include Steven Sherman, Scott G Davis, Jerome Wong and Jason C Jones.
View institutional ownership trends.

How do I buy shares of Ekso Bionics?

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ekso Bionics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ekso Bionics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), TransEnterix (TRXDW), Meta Platforms (META), Tesla (TSLA), Editas Medicine (EDIT) and Micron Technology (MU).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 5/18/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: General industrial machinery,
• Sub-Industry: Machinery
• Current Symbol: NASDAQ:EKSO
• Previous Symbol: OTCMKTS:EKSOD
• CIK: 1549084
• Web: www.eksobionics.com
• Phone: (510) 984-1761
• Fax: 510-927-2647
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.50
• High Stock Price Target: $4.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +567.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-15,200,000.00
• Net Margins: -62.95%
• Pretax Margin: -62.95%
• Return on Equity: -83.09%
• Return on Assets: -39.03%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 2.81
• Quick Ratio: 2.14

Sales & Book Value

• Annual Sales: $17.54 million
• Price / Sales: 0.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.85 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 29,043,000
• Free Float: 20,656,000
• Market Cap: $10.87 million
• Optionable: Optionable
• Beta: 1.09